Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd

EP: 1.Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

EP: 2.Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers

EP: 3.Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers

EP: 4.Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs

EP: 5.Sequencing Therapy in MBC in Second Line and Beyond

EP: 6.Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy

EP: 7.Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers

EP: 8.Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers

EP: 9.A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer

EP: 10.Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

EP: 11.First- and Second-Line Treatment Options for HER2+ Gastric Cancer

EP: 12.T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs

EP: 13.Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer

EP: 14.Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea

EP: 15.T-DXd in HER2+ Gastric Cancer: Educating Patients About Risk of Diarrhea

Now Viewing

EP: 16.Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd

EP: 17.Novel Clinical Trials With ADCs in Gastric Cancer

EP: 18.Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer

Transcript:

Sarah Donahue, MPH, NP, AOCNP: How does your broader health care team, where you practice, participate in the management of these toxicities in patients with trastuzumab deruxtecan in metastatic gastric cancer. Theresa?

Theresa Wicklin Gillespie, PhD, MA, RN, FAAN: We do have very good pharmacy support. We have Pharm Ds [doctors of pharmacy] that are part of the team. And if the regimen that Liz Elizabeth Prechtel Dunphy, DNP, CRNP, AOCN went over, perhaps, is not effective in a particular patient, or they have some other things going on, that input may be very valuable. And then, absolutely, nutritional support. We have dietitians who are very engaged with these patients and their families in terms of helping them to work through these nutritional issues. And so they would be, I would say, top of the list in terms of the broader health care providers who would need to be involved with these patients.

Jamie Carroll, APRN, CNP, MSN: I definitely agree. We have clinical pharmacists on our care teams. Our clinical RNs [registered nurses] obviously play a pivotal role in talking with patients about toxicities. They do our education prior to the patient starting a new therapy. They’re that frontline when a patient messages into the care team. So the nurses do a lot of our toxicity management for our patients.

Sarah Donahue, MPH, NP, AOCNP: We have a similar setup where we are. We call them our triage nurses that are the first line in hearing about changes in bowel movements.

Transcript edited for clarity.